Statistics from Altmetric.com
An 83-year-old female with prior 23-mm Mitroflow biological prosthetic aortic valve replacement (Sorin Group Inc, Mitroflow Division, Vancouver, Canada), symptomatic severe periprosthetic regurgitation and preserved left ventricular ejection fraction was referred for transcatheter aortic valve implantation (TAVI). Preprocedural catheterisation showed normal coronary arteries and severe aortic regurgitation. Although TAVI is licensed for treating native valve aortic stenosis it can be used off label for treating bio-prosthetic valve failure due to aortic regurgitation.
A 23-mm Edwards SAPIEN transcatheter aortic prosthetic valve (Edwards Lifesciences, Irvine, California, USA) via right femoral artery was deployed. Due to persistence of severe …
Contributors According to the definition given by the International Committee of Medical Journal Editors (ICMJE), three authors made one or more of the substantial contributions to the intellectual content (conception and design, acquisition of data). Furthermore, three authors participated in drafting of the manuscript.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.